Declaration of Voting Results & Voting Rights Announcements • Mar 28, 2013
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Uppsala, Sweden – March 28, 2013 - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants.
Today, the last trading day of the month, there are in total 30,002,582 shares and votes in the company.
Carl-Johan Blomberg, CFO Tel: +46-706 33 67 11, Email: [email protected]
Orexo AB is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology. Orexo's expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue generating EU and US approved products currently marketed under licence and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharma companies. Orexo AB is headquartered in Sweden has 90 employees and is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.
For information about Orexo please visit www.orexo.com
Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 4:30 pm CET on March 28, 2013.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.